Omnicell (OMCL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

Importantly, our data indicates that Omnicell's profit was reduced by US$9.9m, due to unusual items, over the last year. It's never great to see unusual items costing the company profits ...

Omnicell, Inc. OMCL has witnessed strong momentum in the past year. Shares of the company have risen 41.6% against a 11.3% decline of the industry during the same time frame. The S&P 500 composite has ...

In the latest quarter, 4 analysts provided ratings for Omnicell OMCL, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the ...

Shares of Omnicell, Inc. (NASDAQ:OMCL – Get Free Report) have received a consensus rating of “Hold” from the six ratings firms that are presently covering the stock, MarketBeat.com reports.

Omnicell , Inc. (NASDAQ:OMCL), a leading provider of medication management solutions in the healthcare technology sector, has been navigating a complex market environment characterized by both ...

Omnicell specializes in automated healthcare solutions, focusing on medication and supply management across the continuum of care. The company's market capitalization stood at approximately $1.85 ...